bluebird bio price target raised to $58 from $51 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio (BLUE) shares to $58 saying the beta thal market provides opportunity for both bluebird and Biogen (BIIB). Piper sees a possible market split should both companies' data remain positive. It keeps an Overweight rating on bluebird bio.
Credit Suisse to hold a conference Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link